Uptravi
(Selexipag)ApprovedSmall molecule
Johnson & JohnsonSelexipag is used to treat pulmonary arterial hypertension, a condition where blood vessels in the lungs become narrowed, making it harder for the heart to pump blood through them. It helps relax these blood vessels and improve blood flow.[2] Uptravi is currently approved and in use across 7 indications[4].[1]
Uptravi is one of 127 small molecule programs targeting Idiopathic Pulmonary Arterial Hypertension. It is currently in Approved.
7
Indications
25
Total Trials
5
Active Trials
126
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
179 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Uptravi
Johnson & JohnsonApproved
Gleevec
NovartisPhase 3
Reata
BiogenPhase 3
Levitra
BayerPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Flolan
Johnson & JohnsonPhase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Atrovent
Boehringer IngelheimPhase 3
Inhaled Iloprost
BayerPhase 3
Medrol
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Arterial Hypertension9 trials
Show 6 more trials
ART2 trials
Pulmonary Hypertension2 trials
TED1 trial
10 more indications
Concentration1 trial
Clopidogrel1 trial
Non-healing Wound1 trial
Interaction1 trial
Cardiac Repolarization1 trial
Hypertension, Pulmonary1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 21, 2015
UPTRAVI
NDA NDA207947
Jul 29, 2021
UPTRAVI
NDA NDA214275
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Uptravi drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Selexipag. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Prostanoid IP Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Oct 31, 2026
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7205302Oct 31, 2026
7205302*PEDApr 30, 2027
9173881Aug 12, 2029
9173881*PEDFeb 12, 2030
9284280Jun 25, 2030
7 more patents
8791122Aug 1, 2030
9284280*PEDDec 25, 2030
8791122*PEDFeb 1, 2031
10828298Dec 1, 2036
10821108Dec 1, 2036
10828298*PEDJun 1, 2037
10821108*PEDJun 1, 2037